Adcytherix
San Diego, United States· Est.
ADC company with novel payload classes. Lead ADCX-020 in Phase 1 for solid cancers (Feb 2026). Built by team behind Emergence Therapeutics (acquired by Eli Lilly).
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $105M
About
ADC company with novel payload classes. Lead ADCX-020 in Phase 1 for solid cancers (Feb 2026). Built by team behind Emergence Therapeutics (acquired by Eli Lilly).
OncologyAntibodies
Funding History
1Total raised:$105M
PIPE$105M